Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The development of targeted agents for thyroid malignancy is reviewed, with a special focus on lenvatinib, a multikinase inhibitor, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future.
Abstract: Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumorigenesis of thyroid cancers has led to development of new targeted agents for the management of advanced and refractory disease. Multikinase inhibitors that are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer have been the most widely studied. After an international effort to identify and recruit sufficient patients, four placebo-controlled studies of multikinase inhibitors have been completed. These trials have led to the approval of the first agents with activity in advanced medullary thyroid cancers, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future. The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.
68 citations
••
TL;DR: PD-L1 may contribute to immune escape in UBC, a disease of high mutational complexity and immunogenicity and MPDL3280A was designed to restore T cell–mediated antitumor activity by restoring PD-L 1 activity.
Abstract: 4501 Background: PD-L1 may contribute to immune escape in UBC, a disease of high mutational complexity and immunogenicity. MPDL3280A was designed to restore T cell–mediated antitumor activity by bl...
67 citations
••
TL;DR: Staging of Squamous cell head and neck cancer should be staged according to the TNM system and grouped into categories shown in Table 1.
67 citations
••
TL;DR: Crizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer and by independent radiologic review, safety, health-related quality of life, and molecular characterization of tumor tissue.
67 citations
••
Memorial Sloan Kettering Cancer Center1, University College Dublin2, University of Texas MD Anderson Cancer Center3, Hebron University4, Peter MacCallum Cancer Centre5, University of Southern California6, Harvard University7, Vanderbilt University8, University of Texas Southwestern Medical Center9, University of Miami10, University of Pittsburgh11, Institut Gustave Roussy12, Yonsei University13, University of Tennessee Health Science Center14, University of Valencia15, Curie Institute16
TL;DR: Activity of the irreversible pan-HER kinase inhibitor neratinib is explored in 81 patients with HER2-mutant metastatic breast cancer and co-existence of additional HER signaling alterations is suggested to promote both de novo and acquired resistance to Neratinib.
Abstract: HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data define HER2 mutations as a therapeutic target in breast cancer and suggest that coexistence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib. SIGNIFICANCE: HER2 mutations define a targetable breast cancer subset, although sensitivity to irreversible HER kinase inhibition appears to be modified by the presence of concurrent activating genomic events in the pathway. These findings have implications for potential future combinatorial approaches and broader therapeutic development for this genomically defined subset of breast cancer.This article is highlighted in the In This Issue feature, p. 161.
67 citations
Authors
Showing all 2723 results
Name | H-index | Papers | Citations |
---|---|---|---|
José Baselga | 156 | 707 | 122498 |
M. I. Martínez | 134 | 1251 | 79885 |
Josep Tabernero | 111 | 803 | 68982 |
Jordi Rello | 103 | 694 | 35994 |
Xavier Montalban | 95 | 762 | 52842 |
James M. Downey | 91 | 381 | 29506 |
Enriqueta Felip | 83 | 622 | 53364 |
Joaquim Bellmunt | 82 | 660 | 41472 |
Joan Montaner | 80 | 489 | 22413 |
Marc Miravitlles | 76 | 651 | 25671 |
David H. Salat | 75 | 241 | 36779 |
Eduard Gratacós | 75 | 531 | 20178 |
Alex Rovira | 74 | 356 | 19586 |
Ramon Bataller | 72 | 283 | 19316 |
Maria Buti | 71 | 493 | 26596 |